CDRT15L2 Inhibitors
CDRT15L2 inhibitors are apart of part of the PI3K/AKT pathway, compounds such as LY294002 and Wortmannin can act by hindering PI3K activity, thereby attenuating subsequent AKT phosphorylation and activity. In the case of involvement in the MAPK/ERK pathway, MEK inhibitors like U0126 and PD98059 can disrupt the pathway, which might indirectly reduce CDRT15L2 activity if it is regulated by or regulating this pathway.
Compounds like Rapamycin and Bortezomib operate on a broader scale, with Rapamycin inhibiting mTOR, a key regulator of cell growth and proliferation, and Bortezomib impairing proteasome function, which could lead to increased levels of proteins, including possibly CDRT15L2, if it is prone to degradation by the ubiquitin-proteasome system. Other compounds listed may affect kinases such as Src or JNK, which are involved in various signaling cascades, or proteins such as ROCK that play roles in cytoskeletal organization. Inhibitors like Dasatinib, PP2, and SP600125 would thus be relevant if CDRT15L2 is part of or regulated by these pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, potentially reducing downstream signaling that CDRT15L2 could be involved in if it plays a role in PI3K/AKT pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAP kinase, potentially affecting inflammatory response pathways that could intersect with CDRT15L2 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which could impact the MAPK/ERK pathway, potentially influencing CDRT15L2 if it is part of this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which could affect cell growth and proliferation pathways that CDRT15L2 might be a part of. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Irreversible PI3K inhibitor, potentially disrupting PI3K-dependent pathways possibly involving CDRT15L2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src kinase inhibitor, which could affect various cellular processes, potentially altering CDRT15L2's functional context if it is associated with Src signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Another Src family kinase inhibitor, which could have similar effects as Dasatinib on CDRT15L2-related pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially impacting stress response pathways that might engage CDRT15L2. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK, which could affect cytoskeletal organization and related signaling, potentially involving CDRT15L2 if it is connected to these processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, potentially affecting the degradation pathways of proteins including hypothetically CDRT15L2. | ||||||